The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatment.

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at slowing cognitive decline in patients. In July, the Amsterdam-based European Medicines Agency (EMA) denied recommending approval of the drug made by Eisai and Biogen because it considered the risks - especially bleeding and swelling in the brain - to be greater than the potential benefits in a broad population.

The European Parliament demanded further changes to a landmark law to tackle global deforestation, adding complications to a plan to delay the controversial rules before they take effect later this year.

The European Parliament voted on Thursday for a 12-month delay to the implementation of a law banning the import of commodities linked to deforestation, and adopted a series of amendments to weaken the law itself.

The European Parliament on Thursday approved a one-year delay on implementing the bloc's sweeping anti-deforestation rules but also voted to loosen some requirements -- raising fresh uncertainty over